Company intelligence / Profile preview

Akesios

Guangzhou, Guangdong Province, Chinaakesios-dialysis.gr ↗

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Akeso has achieved significant milestones with approvals of novel bispecific antibodies such as cadonilimab and ivonescimab for major solid tumors. The company has over two dozen candidates in clinical trials with more than twenty Phase III studies ongoing or completed. Their bispecific antibodies have shown promising efficacy against cancers like lung, gastric, cervical cancers. They also have approved products included in national insurance schemes enhancing patient access[2][5].

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateBispecific ADCsRecombinant protein therapies
Industry: Biotech

Beyond the preview

Go deeper on Akesios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akesios.

Explore the full profile